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INTRODUCTION
Demyelinating diseases of the central ner-
vous system (CNS) affect prevalently
young adults and represent the main
cause of neurological disability after
trauma in this population (1). Multi-
ple sclerosis (MS), acute disseminated
encephalomyelitis (ADEM), and neu-
romyelitis optica (NMO) are the most
common inflammatory-demyelinating
disorders of the CNS (1, 2).
Multiple sclerosis shares several features
with antiphospholipid syndrome (APS)
including the clinical presentation, the
relapsing–remitting course, the higher inci-
dence in females of childbearing age, and
the presence of similar white matter (WM)
lesions at MRI (3). Likewise, both neu-
rological symptoms and MRI lesions may
overlap in ADEM and in the initial presen-
tation of APS (4). Therefore, MS, ADEM,
and APS are part of the reciprocal differ-
ential diagnosis (2). APS represents also
one of the main risk factors for cere-
bral venous thrombosis (CVT) (5), which
is not usually included in the differen-
tial diagnosis of demyelinating diseases.
However, several reports in literature have
described an association between CVT and
MS (6–9).
Although an accurate differential diag-
nosis is desirable for ensuring a more
targeted therapy, the examination of the
shared features between thrombotic and
demyelinating diseases of the CNS would
help to understand their common patho-
genic mechanisms.
SPECIFICITY AND SIMILARITIES OF
THROMBOTIC AND DEMYELINATING
DISEASES
CEREBRAL VENOUS THROMBOSIS
Cerebral venous thrombosis of dural sinus
and/or large veins is considered as a rare
form of cerebrovascular disease (0.5–1%
of all strokes) (5, 10, 11), though a previous
pathological study found higher prevalence
of CVT (9.3%) in 182 consecutive autop-
sies (12). Although firstly recognized as an
infective disease, CVT is now considered
as a non-septic condition (11). Infections,
however, mainly parameningeal, are rec-
ognized as a common cause of CVT in
children (up to 40% of cases) (5). Other
predisposing factors include both acquired
(APS, pregnancy, puerperium, oral contra-
ceptives, surgery, head trauma, dehydrata-
tion, cancer, and parameningeal infections)
and genetic (deficiency of antithrombin-
III, protein C and S, factor V Leiden pos-
itivity) conditions (5). CVT can occur at
any age but it is more common in young
people: in the largest cohort study, it has
been reported that 78% of cases occur in
patients younger than 50 years (13). The
diagnosis of CVT is challenging in rou-
tine practice because the clinical manifes-
tations may mimic several other diseases
and may be restricted to isolated headache
in up to 25% of patients (5). No labora-
tory parameters are diagnostic of CVT or
can rule out it, as, for instance, a normal
d-dimer level. Brain MRI frequently shows
non-specific lesions, such as hemorrhages,
infarcts, edema, and diffuse brain swelling
or may be normal in up to 25% of cases.
Gradient-echo and susceptibility-weighted
MR imaging may increase CVT diagnostic
sensitivity, especially in the early throm-
botic stages (5). The overall prognosis of
CVT is better than that of arterial stroke,
with complete recovery in about two-thirds
of cases (11).
ACUTE DISSEMINATED ENCEPHALOMYELITIS
Acute disseminated encephalomyelitis is a
monophasic demyelinating disease of CNS,
which typically ensues to viral or bac-
terial infections and vaccinations occur-
ring prevalently in children during the
winter and spring (4, 14, 15). The isola-
tion of a specific pathogen is uncommon
despite the high prevalence of many neu-
rotropic pathogens in the general popula-
tion. The clinical symptoms are frequently
non-specific such as headaches, fever, and
lethargy, while MRI detects widespread,
multifocal, and extensive white and deep
gray matter lesions with poorly defined
margins, and sometimes large, swollen,
thoracic cord lesions, completely resolv-
ing in up to half of the cases. There is
a report of even normal MRI in ADEM
(16). Furthermore, in acute hemorrhagic
leukoencephalitis, a severe and rare variant
of ADEM, large WM lesions with edema,
mass effect and even obvious hemor-
rhages are detected on MRI (1). Although
the MRI features of ADEM have not
been clearly established, a recent study
demonstrated a prevalently vasogenic
edema (17).
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Despite CVT and ADEM are not usually
part of the reciprocal differential diagnosis,
the MRI characteristics of ADEM as well
as its clinical presentation and evolution
appear more similar to CVT rather than to
MS. It should be also highlighted that large
thoracic lesions reported in ADEM are a
hallmark of APS in differential diagnosis
with MS (3).
ANTIPHOSPHOLIPID SYNDROME
The diagnostic criteria of APS include arte-
rial/venous thrombosis and/or fetal loss,
and the persistence of specific antiphos-
pholipid antibodies (aPL) at medium or
high titer for at least 12 weeks (18).
APS might be associated with infec-
tions (19, 20).
Antiphospholipid antibodies are not
exclusive of APS and may be found less
steadily and/or in low titers in infections
(21), in CVT (5), and in several autoim-
mune diseases including MS (22–25) and
NMO spectrum disorders (NMOSD) (26).
Reactivity for aPL and other autoantibod-
ies has been reported more frequently in
NMOSD compared to MS (26, 27), con-
firming the already known higher occur-
rence of aPL in “neuromyelitic” type of
MS (28).
NEUROMYELITIS OPTICA
Neuromyelitis optica is a more severe
demyelinating disorder compared to MS.
It is characterized by optic neuritis, longi-
tudinally extensive myelitis (three or more
spinal segments on MRI), and autoanti-
body positivity against the water chan-
nel aquaporin-4 (2, 29). Large spinal cord
lesions, similar to those of APS and ADEM,
represent one of the diagnostic criteria for
NMO. Recently, anti-cardiolipin antibod-
ies in NMO patients have been associated
with greater antithrombin-III activity and
d-dimer levels, a product of fibrin degrada-
tion, suggesting the involvement of throm-
botic pathogenic mechanisms in this dis-
order (26, 30). Moreover, several studies
supported the association between NMO
and various infections (31–33).
MULTIPLE SCLEROSIS
Multiple sclerosis is a chronic disorder
of the CNS pathologically characterized
by inflammation, demyelination, and neu-
rodegeneration. MS usually begins with
a relapsing–remitting course manifesting
with relapses, commonly followed by a sec-
ondary progressive phase characterized by
steady accumulation of disability. As men-
tioned before, aPL can be detectable in MS,
and their reactivity appears to be related to
the severity of the MS stage: aPL reactivity
is higher in secondary progressive MS than
in relapsing–remitting MS, and particu-
larly during the relapses (up to 80%) (22–
25). Interestingly, aPL reactivity decreases
over few months after relapse. Further-
more, aPL positive relapsing–remitting MS
patients develop more severe clinical and
MRI disease progression over a 3-year
follow-up compared to aPL negative MS
cases (34).
Multiple sclerosis is associated with
an increased risk of venous thromboem-
bolism (35). CVT has been also reported in
MS, being generally attributed to lumbar
puncture and/or to the effects of methyl-
prednisolone therapy, but in some cases,
it was not associated with any predispos-
ing state (6–9). Furthermore, some condi-
tions that favor thrombosis such as cranial
radiation, CNS trauma, and puerperium
may promote MS reactivation (36). Also
stress, producing significant hemoconcen-
tration and pro-thrombotic blood changes
(37), might foster MS relapse. However, the
main risk factors for MS re-exacerbations
are represented by infections, mostly viral
(36). Viruses are considered to be the prin-
cipal environmental factors associated with
MS as suggested by epidemiological and
genetic studies (38), as well as by the life-
long presence of oligoclonal IgG in the
cerebrospinal fluid in the majority of MS
patients (39).
DISCUSSION
The close clinical and radiological similar-
ities between inflammatory-demyelinating
and thrombotic diseases of the CNS sug-
gest the presence of common underlying
events. There is a striking incongruence
regarding the prevalence of CVT, com-
monly acknowledged to represent 0.5–1%
of all strokes, but found in the 9.3% of con-
secutive autopsies. This apparent incon-
gruence can be partially explained not only
by the difficulty of CVT clinical diagno-
sis but also by the lower occurrence of
CVT of dural sinus or large veins compared
to the thrombosis of smaller veins occur-
ring, for example, in APS. Thus, on the
basis of similar clinical and MRI features
of CVT and ADEM, it can be hypothe-
sized that inflammatory-thrombotic events
take part in the pathophysiology of ADEM,
even if to a lesser extent. In the same
way, the characteristics of spinal cord
lesions as well as a high frequency of
aPL associated with increased coagulation
indicators may suggest the presence of
inflammatory-thrombotic phenomena in
NMO. Indeed, further MR-based studies
assessing brain and spinal cord venous
blood dynamics are needed to confirm such
hypothesis.
Similarly, the association of MS with
an increased risk of venous thromboem-
bolism reported in epidemiological stud-
ies, as well as the correlation between MS
exacerbations and pro-thrombotic factors
including aPL positivity, would suggest
that MS pathogenic mechanisms may, at
least in part, involve thrombotic processes
(40). Moreover, in experimental allergic
encephalomyelitis (EAE), fibrin deposition
precedes and regulates the inflammatory
demyelination, while its genetic or phar-
macologic depletion ameliorates both clin-
ical symptoms and inflammatory response
(41). Early perivascular microglial clus-
tering is blocked by anticoagulant treat-
ment or by genetic depletion of fibrino-
gen in EAE (42). Thrombin, which has
numerous hormone-like functions affect-
ing microglia and astrocytes, was pro-
posed as a therapeutic target in MS
(43). On the other hand, the concept of
thrombo-inflammation was recently intro-
duced since ischemic stroke has been
defined as a thrombo-inflammatory dis-
ease (44). Indeed, both innate and adaptive
immunity are involved during all stages
of stroke (45). The inhibition of plasma
kallikrein, a key constituent of the proin-
flammatory contact-kinin system, is effec-
tive in wild-type mice up to 3 h post
stroke (46). In fact, the contact-kinin sys-
tem, representing an interface between
inflammatory and thrombotic systems, was
found activated in different neurologi-
cal diseases, such as in traumatic brain
injury showing a microvascular thrombo-
sis along with edema and immune cell
infiltration (47). The data reported in this
work would suggest that the concept of
thrombo-inflammation is also appropriate
for the inflammatory-demyelinating dis-
eases, albeit with quantitatively varying
expression.
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Inflammation and coagulation repre-
sent the main components of innate
immunity, an universal immediate defense
against infections, which stimulates and
modulates the adaptive one. Thrombotic
events occur when coagulation processes
prevail over the natural anticoagulant sys-
tem (48). Therefore, the presence of throm-
bosis should indicate the occurrence of
intense and/or prolonged inflammatory-
thrombotic processes. This could take
place in the course of subclinical chronic
infections prevalently in individuals with
a reduced anticoagulant and/or anti-
oxidative capacity, resulting in their indi-
vidual susceptibility to these diseases. All
disorders described above occur preva-
lently in the young age, characterized by
a first contact with external pathogens,
and are closely linked with concomitant or
immediately preceding clinical infections.
It is more realistic to assume that a massive
and steady response of innate immunity is
triggered directly by the pathogen rather
than by an indirect autoimmune reaction.
Even autoantibodies including aPL may be
an expression of a reaction against the self-
components damaged during infections or
injury similarly to physiological process of
elimination of aged cells and proteins.
In conclusion, we speculate that
demyelinating and thrombotic diseases
of the CNS share widespread occurrence
of inflammatory-thrombotic processes.
The triggering factors underlying these
processes are still unknown. Inflammatory
and coagulant pathways are closely linked
during activation of the innate immune
system. Hence, it is possible that common
pathogenic factors, including subclinical
chronic infections, exert their role at the
level of the innate immune system in genet-
ically or environmentally induced sus-
ceptible individuals. This viewpoint does
not aim to belittle the importance of
specific characteristics of these diseases,
which could be related to different causal
pathogens together with concomitant and
genetic factors, but it is aimed to find their
reciprocal factual connections in order to
better control them and develop more
appropriate therapeutic strategies.
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